Gilead Sciences Inc.
Gilead Sciences Appoints New Chief Medical Officer
Summary
Gilead Sciences, Inc. announced on December 12, 2024, the appointment of Dietmar Berger, MD, PhD, as its new Chief Medical Officer, effective January 2, 2025. Dr. Merdad Parsey, the current Chief Medical Officer, will remain as a Senior Advisor until the first quarter of 2025. Dr. Berger, with over 25 years of experience in drug development, will lead Gilead's virology, oncology, and inflammation portfolios and oversee global Development and Medical Affairs. The appointment follows a strategic transition aimed at leveraging Dr. Berger's expertise to advance Gilead's therapeutic pipeline.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement